Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

β-catenin is dynamically stored and cleared in multiple myeloma by the proteasome–aggresome–autophagosome–lysosome pathway

Leukemia volume 26, pages 1116–1119 (2012)Cite this article

Multiple myeloma (MM) is a malignant proliferation of plasma cells (PCs) in the bone marrow (BM). Activation of the canonical WNT/β-catenin signaling pathway is a frequent event in MM;1, 2, 3, 4 however, the molecular mechanisms underlying this phenomenon remain unknown. In contrast to most epithelial cancers, MM lacks mutations in critical components of this pathway, suggesting that deregulated post-translational mechanisms contribute to the aberrant expression of WNT pathway proteins.1, 5 We and others have documented the overexpression of the central WNT signaling molecule, β-catenin, in a majority of MM PCs as compared with normal PCs.1, 2, 3, 6, 7 Post-translational regulation of β-catenin is typically mediated through phosphorylation events that tag the protein for ubiquitination and degradation through the 26S proteasome. In most cellular contexts, the ubiquitin–proteasome system (UPS) is sufficient to handle normal protein synthesis, misfolding and turnover;8 however, exceeding the capacity of the UPS causes polypeptides to accumulate in cytosolic aggregates near the perinuclear microtubule organizing center. Continued stress on the UPS causes additional protein aggregates to amass, forming a dense structural assembly termed the aggresome.9 Aggresomes recruit additional protein catabolic machinery to aid in the unfolding of compacted proteins for proteasomal or autophagosomal/lysosomal removal.10 Thus, aggresome formation provides a reserve protein processing unit to the proteasome to eliminate unwanted proteins.

We suspected that β-catenin could be used as a marker of aggresomes to identify malignant PCs in patient samples. We therefore evaluated the staining pattern in MM paraffin-embedded biopsies using two different antibodies that recognize distinct epitopes of β-catenin. In accordance with the IHC and SEM findings described above, use of either β-catenin antibody revealed a strong perinuclear signal (Supplementary Figure 2). The occurrence of aggresomes in MM cells was also verified with aggresomal markers ubiquitin and vimentin (Supplementary Figure 3); however, we found β-catenin to be a more reliable marker for aggresomes in IHC. We expanded our analysis to include normal (n=20) and MM BM biopsies (n=90) using tissue microarrays; PCs were identified with an anti-CD138 antibody. In all normal samples, β-catenin expression in PCs was barely, if at all, detectable (Figure 1f). Strikingly, greater than 90% of MM cases showed aggresomal β-catenin and nearly all MM cells contained aggresomes (Figure 1f and Supplementary Figure 4). Thus, our data show that aggresomal β-catenin expression is nearly universal in MM, but absent from normal PCs, which highlights its potential use as a biomarker for malignant PCs.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Derksen PW, Tjin E, Meijer HP, Klok MD, MacGillavry HD, van Oers MH et al. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci USA 2004; 101: 6122–6127.

    Article  CAS  Google Scholar 

  2. Sukhdeo K, Mani M, Zhang Y, Dutta J, Yasui H, Rooney MD et al. Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci USA 2007; 104: 7516–7521.

    Article  Google Scholar 

  3. Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 2006; 9: 313–325.

    Article  CAS  Google Scholar 

  4. Bjorklund CC, Ma W, Wang ZQ, Davis RE, Kuhn DJ, Kornblau SM et al. Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem 2011; 286: 11009–11020.

    Article  CAS  Google Scholar 

  5. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471: 467–472.

    Article  CAS  Google Scholar 

  6. Dutta-Simmons J, Zhang Y, Gorgun G, Gatt M, Mani M, Hideshima T et al. Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression. Blood 2009; 114: 2699–2708.

    Article  CAS  Google Scholar 

  7. Mani M, Carrasco DE, Zhang Y, Takada K, Gatt ME, Dutta-Simmons J et al. BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. Cancer Res 2009; 69: 7577–7586.

    Article  CAS  Google Scholar 

  8. Ciechanover A, Orian A, Schwartz AL . Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays 2000; 22: 442–451.

    Article  CAS  Google Scholar 

  9. Johnston JA, Ward CL, Kopito RR . Aggresomes: a cellular response to misfolded proteins. J Cell Biol 1998; 143: 1883–1898.

    Article  CAS  Google Scholar 

  10. Fabunmi RP, Wigley WC, Thomas PJ, DeMartino GN . Activity and regulation of the centrosome-associated proteasome. J Biol Chem 2000; 275: 409–413.

    Article  CAS  Google Scholar 

  11. Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 2005; 102: 8567–8572.

    Article  CAS  Google Scholar 

  12. Epstein J, Yaccoby S . The SCID-hu myeloma model. Methods Mol Med 2005; 113: 183–190.

    PubMed  Google Scholar 

  13. Fortun J, Dunn Jr WA, Joy S, Li J, Notterpek L . Emerging role for autophagy in the removal of aggresomes in Schwann cells. J Neurosci 2003; 23: 10672–10680.

    Article  CAS  Google Scholar 

  14. Kolodziejska KE, Burns AR, Moore RH, Stenoien DL, Eissa NT . Regulation of inducible nitric oxide synthase by aggresome formation. Proc Natl Acad Sci USA 2005; 102: 4854–4859.

    Article  CAS  Google Scholar 

  15. Chng WJ, Ahmann GJ, Henderson K, Santana-Davila R, Greipp PR, Gertz MA et al. Clinical implication of centrosome amplification in plasma cell neoplasm. Blood 2006; 107: 3669–3675.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

DRC is supported by R01CA151391-01, the Multiple Myeloma Research Foundation, and is a Sidney Kimmel Foundation Scholar.

Author information

Authors and Affiliations

  1. Department of Stem Cell Biology and Regenerative Medicine, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA

    K Sukhdeo

  2. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

    M Mani, T Hideshima, K Takada, V Pena-Cruz, K C Anderson & D R Carrasco

  3. Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

    T Hideshima & K C Anderson

  4. Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA

    G Mendez & D R Carrasco

  5. Department of Neurobiology, Harvard Medical School, Boston, MA, USA

    S Ito

Authors
  1. K Sukhdeo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Mani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Hideshima
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K Takada
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V Pena-Cruz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G Mendez
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K C Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D R Carrasco
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D R Carrasco.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sukhdeo, K., Mani, M., Hideshima, T. et al. β-catenin is dynamically stored and cleared in multiple myeloma by the proteasome–aggresome–autophagosome–lysosome pathway. Leukemia 26, 1116–1119 (2012). https://doi.org/10.1038/leu.2011.303

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2011.303

This article is cited by

Search

Advanced search

Quick links